Woebot Health Unveils Scientific Advisory Board pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Photo by kate-sept2004/Getty Images
Digital mental health company Woebot Health has landed FDA Breakthrough Device Designation for its postpartum depression digital therapeutic, WB001.
WB001 combines cognitive behavioral therapy and elements of interpersonal psychotherapy with the company’s conversational chatbot, Woebot, to deliver treatment directly through patients’ phones.
Designed as a prescription digital therapeutic, the eight-week program treats symptoms of postpartum depression through lessons that attempt to normalize and contextualize the postpartum experience.
Specifically, the CBT-based tools help users adjust their behavioral practices through mindfulness and self-care, while the IPT-based tools focus on relationship transitions, communication analysis and skill-building.
The FDA Breakthrough Device Designation aims to give patients access to technologies that have the potential to provide treatment or diagnosis for debilitating diseases or conditions while giv